SG11201706268XA - Tnfrsf-binding agents and uses thereof - Google Patents

Tnfrsf-binding agents and uses thereof

Info

Publication number
SG11201706268XA
SG11201706268XA SG11201706268XA SG11201706268XA SG11201706268XA SG 11201706268X A SG11201706268X A SG 11201706268XA SG 11201706268X A SG11201706268X A SG 11201706268XA SG 11201706268X A SG11201706268X A SG 11201706268XA SG 11201706268X A SG11201706268X A SG 11201706268XA
Authority
SG
Singapore
Prior art keywords
tnfrsf
binding agents
binding
agents
Prior art date
Application number
SG11201706268XA
Inventor
Austin L Gurney
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of SG11201706268XA publication Critical patent/SG11201706268XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
SG11201706268XA 2015-02-03 2016-02-03 Tnfrsf-binding agents and uses thereof SG11201706268XA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562111404P 2015-02-03 2015-02-03
US201562153272P 2015-04-27 2015-04-27
US201562154008P 2015-04-28 2015-04-28
US201562218956P 2015-09-15 2015-09-15
US201562259129P 2015-11-24 2015-11-24
PCT/US2016/016306 WO2016126781A1 (en) 2015-02-03 2016-02-03 Tnfrsf-binding agents and uses thereof

Publications (1)

Publication Number Publication Date
SG11201706268XA true SG11201706268XA (en) 2017-08-30

Family

ID=56564627

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706268XA SG11201706268XA (en) 2015-02-03 2016-02-03 Tnfrsf-binding agents and uses thereof

Country Status (18)

Country Link
US (2) US9724390B2 (en)
EP (1) EP3253890A4 (en)
JP (1) JP2018508233A (en)
KR (1) KR20170108073A (en)
CN (2) CN109180804A (en)
AU (1) AU2016215394A1 (en)
BR (1) BR112017016705A2 (en)
CA (1) CA2975596A1 (en)
CO (1) CO2017008047A2 (en)
EA (1) EA201791313A1 (en)
HK (1) HK1243741A1 (en)
IL (1) IL253433A0 (en)
MA (1) MA41460A (en)
MX (1) MX2017009793A (en)
PH (1) PH12017501372A1 (en)
SG (1) SG11201706268XA (en)
TW (1) TW201643184A (en)
WO (1) WO2016126781A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450460B2 (en) * 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
CN107892719B (en) * 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 Human monoclonal anti-PD-L1 antibodies and methods of use
KR102268688B1 (en) 2013-07-19 2021-06-24 브이아이비 브이지더블유 Targeted modified tnf family members
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
RU2714157C2 (en) * 2015-02-06 2020-02-12 Хит Байолоджикс, Инк. Vector, co-expressing molecules for vaccination and costimulatory molecules
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN108368170B (en) 2015-07-13 2022-04-15 西托姆克斯治疗公司 anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
SG10201913597VA (en) 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
US10988543B2 (en) 2015-11-11 2021-04-27 Opi Vi—Ip Holdco Llc Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
MA44993A (en) * 2016-05-13 2019-03-20 Medimmune Llc CD40L-FC FUSION POLYPEPTIDES AND ASSOCIATED PROCEDURES FOR USE
MX2018015853A (en) 2016-07-14 2019-08-21 Genmab As Multispecific antibodies against cd40 and cd137.
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
US20200291089A1 (en) * 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
IL268198B1 (en) 2017-02-27 2024-06-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
JP7121029B2 (en) 2017-02-27 2022-08-17 シャタック ラボ，インコーポレイテッド CSF1R-based chimeric protein
JP7244428B2 (en) * 2017-02-27 2023-03-22 シャタック ラボ，インコーポレイテッド VSIG8-based chimeric protein
WO2018160572A1 (en) * 2017-02-28 2018-09-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising gitr-binding agents
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP3623388A4 (en) 2017-05-08 2021-08-04 Shanghai JMT-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
EP3625260A1 (en) 2017-05-16 2020-03-25 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
JP2020522486A (en) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド Activatable anti-PDL1 antibody and method of using the same
KR102371420B1 (en) * 2017-06-27 2022-03-08 (주)아모레퍼시픽 Composition for skin whitening comrpising tnfsf14 protein
WO2019032945A1 (en) * 2017-08-10 2019-02-14 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
CN111819198A (en) * 2017-12-28 2020-10-23 尤利乌斯·马克西米利安维尔茨堡大学 Tumor Necrosis Factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with non-Fc γ R dependent agonistic activity (TNFRSF receptor-activating antibody fusion proteins with non-Fc γ R dependent agonistic activity; TRAAFFIAA)
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
CA3098374A1 (en) 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
WO2019237383A1 (en) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Modified vector used for human tnfsf18 gene editing, preparation method therefor and application thereof
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
CN111454361B (en) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 Antibodies that bind to CD40 and uses thereof
BR112022007720A2 (en) 2019-10-24 2022-08-23 Prometheus Biosciences Inc HUMANIZED ANTIBODIES TO TNF-LIKE BINDING 1A (TL1A) AND THEIR USES
WO2021229103A2 (en) * 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CA3213285A1 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Bioengineered immunomodulatory fusion protein compositions
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2024107749A1 (en) * 2022-11-16 2024-05-23 Attralus, Inc. Fusion proteins that bind amyloid and the transferrin receptor and uses thereof

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325224B1 (en) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
ES2198414T3 (en) 1992-10-23 2004-02-01 Immunex Corporation PROCEDURES TO PREPARE SOLUBLE OLIGOMERIC PROTEINS.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US5998171A (en) 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
EP0961831B1 (en) * 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Human endokine alpha
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
WO1999025834A1 (en) 1997-11-18 1999-05-27 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
DE69939526D1 (en) 1998-02-24 2008-10-23 Sisters Of Providence In Orego COMPOSITIONS CONTAINING EITHER AN OX-40 RECIPE BINDING OR AN NUCLEIC ACID SEQUENCE ENCODING SUCH A BINDING AGENT AND METHOD FOR IMPROVING THE ANTIGEN-SPECIFIC IMMUNE RESPONSE
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
IL147442A0 (en) 1999-07-12 2002-08-14 Genentech Inc Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
DE19963859A1 (en) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- or oligomer of a di-, tri-, quattro- or pentamer of recombinant fusion proteins
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
DE10122140A1 (en) 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Recombinant fusion proteins and their trimers
US20030133936A1 (en) 2001-07-12 2003-07-17 Byrne Michael Chapman CD25markers and uses thereof
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
JP4488740B2 (en) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Agents that modulate immune cell activation and methods of use thereof
WO2003068977A2 (en) 2002-02-10 2003-08-21 Apoxis Sa Fusion constructs containing active sections of tnf ligands
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
ES2654064T3 (en) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CN101899106A (en) 2002-10-29 2010-12-01 阿纳福公司 The binding proteins for trimeric of trimerization cytokine
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
DE102004014983A1 (en) 2004-03-26 2005-10-20 Univ Stuttgart Recombinant polypeptides of the members of the TNF ligand family and their use
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
HUE039237T2 (en) 2004-10-06 2018-12-28 Mayo Found Medical Education & Res B7-h1 and pd-1 in treatment of renal cell carcinoma
US7696175B2 (en) 2004-10-29 2010-04-13 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
EP1877090B1 (en) 2005-05-06 2014-01-15 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
AU2006254902B8 (en) 2005-06-08 2012-08-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
KR101888321B1 (en) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp Gitr antibodies for the treatment of cancer
US20100015143A1 (en) 2006-03-22 2010-01-21 Tracy Hussell Compositions and Methods Relating to Modulation of Immune System Components
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
MX351975B (en) 2006-12-27 2017-11-06 Emory Univ Star COMPOSITIONS and METHODS FOR THE TREATMENT OF INFECTIONS and TUMORS.
EP2009022A1 (en) 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
EP3072903B1 (en) 2007-07-10 2017-10-25 Apogenix AG Tnf superfamily collectin fusion proteins
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
US20090136446A1 (en) 2007-11-02 2009-05-28 Ludwig Institute For Cancer Research Ltd. Induction of regulatory t cell-resistant helper cd4+ t cells
US20090258013A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US8450460B2 (en) 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
CA2744449C (en) 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
CN103641918A (en) 2009-03-13 2014-03-19 宾夕法尼亚大学董事会 OX40/TRAIL fusion proteins
CA3067609A1 (en) 2009-09-03 2011-03-10 Merck Sharp & Dohme Corp. Anti-gitr antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
IL300733A (en) 2010-03-05 2023-04-01 Univ Johns Hopkins Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
BR112013004266A8 (en) 2010-08-23 2018-01-02 Univ Texas anti-ox40 antibodies and methods of use.
EP3670536A3 (en) * 2011-04-01 2020-10-07 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
US9738707B2 (en) * 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
TWI476001B (en) 2011-12-26 2015-03-11 Ind Tech Res Inst Trimeric fc fusion and uses thereof
US20150073043A1 (en) 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
WO2013119202A1 (en) 2012-02-06 2013-08-15 Providence Health & Services - Oregon Cancer treatment and monitoring methods using ox40 agonists
CN104470949A (en) 2012-05-15 2015-03-25 百时美施贵宝公司 Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
US10081759B2 (en) 2012-10-09 2018-09-25 Eric John Wernimont Method, apparatus, and composition for increased recovery of hydrocarbons by paraffin and asphaltene control from reaction of fuels and selective oxidizers in the subterranean environment
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
ES2715673T3 (en) 2012-12-03 2019-06-05 Bristol Myers Squibb Co Improvement of the anti-cancer activity of immunomodulatory FC fusion proteins
CA2896989A1 (en) 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
ES2775278T3 (en) 2013-03-15 2020-07-24 Geoffrey W Stone Composition consisting of an antigen linked to a ligand of the TNF superfamily
ES2819209T3 (en) 2013-07-16 2021-04-15 Hoffmann La Roche Cancer treatment procedures using PD-1 axis binding antagonists and TIGIT inhibitors
KR102268688B1 (en) 2013-07-19 2021-06-24 브이아이비 브이지더블유 Targeted modified tnf family members
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
WO2015197874A2 (en) 2014-06-27 2015-12-30 Apogenix Gmbh Combination of cd95/cd95l inhibition and cancer immunotherapy
US9914761B2 (en) 2014-07-10 2018-03-13 Washington University Oligomers for TNF superfamily inhibition
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
RU2017120063A (en) 2014-11-11 2018-12-13 Медиммьюн Лимитед THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF NEOPLASIA
RS61870B1 (en) 2014-11-14 2021-06-30 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
CN107709364A (en) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 Antigen binding complex and application method with agonist activity
MX2018000948A (en) 2015-07-23 2018-09-27 Inhibrx Inc Multivalent and multispecific gitr-binding fusion proteins.
EP3334758A1 (en) 2015-08-12 2018-06-20 Medimmune Limited Gitrl fusion proteins and uses thereof
AU2016341402B2 (en) 2015-10-23 2020-08-27 Apogenix Ag Single-chain GITR-receptor agonist proteins

Also Published As

Publication number Publication date
WO2016126781A4 (en) 2016-10-13
KR20170108073A (en) 2017-09-26
MX2017009793A (en) 2017-10-27
EP3253890A1 (en) 2017-12-13
CN109180804A (en) 2019-01-11
HK1243741A1 (en) 2018-07-20
BR112017016705A2 (en) 2018-04-10
PH12017501372A1 (en) 2017-12-18
MA41460A (en) 2017-12-12
CA2975596A1 (en) 2016-08-11
TW201643184A (en) 2016-12-16
US20160256527A1 (en) 2016-09-08
US20180021407A1 (en) 2018-01-25
US9724390B2 (en) 2017-08-08
CN107406878A (en) 2017-11-28
AU2016215394A1 (en) 2017-08-03
IL253433A0 (en) 2017-09-28
US10232017B2 (en) 2019-03-19
EA201791313A1 (en) 2018-02-28
EP3253890A4 (en) 2018-06-27
WO2016126781A1 (en) 2016-08-11
JP2018508233A (en) 2018-03-29
CO2017008047A2 (en) 2018-01-05

Similar Documents

Publication Publication Date Title
HK1243741A1 (en) Tnfrsf-binding agents and uses thereof
IL255577B (en) Tigit-binding agents and uses thereof
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2-
IL264813B (en) 2-oxo-imidazopyridines and their use
SG11201706029VA (en) Anti-senescence compounds and uses thereof
HK1246780A1 (en) Aza-pyridone compounds and uses thereof
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201504763D0 (en) Compounds and uses
GB201616439D0 (en) Compounds and uses
HK1247122A1 (en) Combinations and uses thereof
IL254241A0 (en) Etv2 and uses thereof
IL264473A (en) Gpr156 variants and uses thereof
HK1250915A1 (en) Composition and uses thereof
SG11201701717UA (en) Antiviral agents and uses thereof
IL253459B (en) Isoergoline compounds and uses thereof
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
GB2545167B (en) Cloches and use thereof
GB2543375B (en) Compounds and their uses
GB201512216D0 (en) Agents uses and methods
GB201514770D0 (en) Compounds and their use
GB201510548D0 (en) Anti-microbial agents and uses therefor
GB201500278D0 (en) Novel combination and use